Growth Metrics

BridgeBio Pharma (BBIO) Gains from Investment Securities (2018 - 2026)

BridgeBio Pharma recorded quarterly Gains from Investment Securities of $4.1 million in Q1 2026, down 45.17% quarter-over-quarter from $7.4 million in Q4 2025, and up 19300.0% year-over-year from N/an in Q1 2025.

BridgeBio Pharma's Gains from Investment Securities history runs 9 years deep, the most recent figure standing at $4.1 million for Q1 2026.

  • In Q1 2026, Gains from Investment Securities rose 19300.0% year-over-year to $4.1 million; the TTM figure through Mar 2026 stood at $14.6 million (up 733.43% YoY), while the FY2025 annual figure was $14.2 million, up 1302.72% from the prior year.
  • Gains from Investment Securities came in at $4.1 million for Q1 2026 at BridgeBio Pharma, down from $7.4 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $7.4 million in Q4 2025 to a low of -$5.2 million in Q4 2024.
  • A 5-year average of $537235.5 and a median of $85374.0 in 2023 frame the typical range for Gains from Investment Securities.
  • Across the five-year window, Gains from Investment Securities plunged 303.01% in 2024 and soared 19300.0% in 2026, its largest moves.
  • BridgeBio Pharma's Gains from Investment Securities stood at -$3.6 million in 2022, then surged by 170.56% to $2.6 million in 2023, then slumped by 303.01% to -$5.2 million in 2024, then soared by 243.24% to $7.4 million in 2025, then slumped by 45.17% to $4.1 million in 2026.
  • According to Business Quant data, Gains from Investment Securities over the past three periods registered $4.1 million, $7.4 million, and $3.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn -
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn
7 Evaxion A 64.16 Bn 64.14 Bn -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn
10 BridgeBio Pharma 12.91 Bn 11.98 Bn 184.58 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 4.07 Mn
Mar 31, 2026 4.07 Mn
Dec 31, 2025 7.43 Mn
Dec 31, 2025 7.43 Mn
Sep 30, 2025 3.03 Mn
Sep 30, 2025 3.03 Mn
Jun 30, 2025 308,006.00
Jun 30, 2025 308,006.00
Mar 31, 2025 21,000.00
Mar 31, 2025 21,000.00
Dec 31, 2024 -5.19 Mn
Dec 31, 2024 -5.19 Mn
Sep 30, 2024 401,924.00
Sep 30, 2024 401,924.00
Jun 30, 2024 56,159.00
Jun 30, 2024 56,159.00
Mar 31, 2024 78,915.00
Mar 31, 2024 78,915.00
Dec 31, 2023 2.56 Mn
Dec 31, 2023 2.56 Mn
Sep 30, 2023 87,584.00
Sep 30, 2023 87,584.00
Jun 30, 2023 85,374.00
Jun 30, 2023 85,374.00
Mar 31, 2023 314,000.00
Mar 31, 2023 314,000.00
Dec 31, 2022 -3.62 Mn
Dec 31, 2022 -3.62 Mn
Sep 30, 2022 53,788.00
Sep 30, 2022 53,788.00
Jun 30, 2022 54,254.00
Jun 30, 2022 54,254.00
Mar 31, 2022 -604,000.00
Mar 31, 2022 -604,000.00
Dec 31, 2021 -11.13 Mn
Dec 31, 2021 -11.13 Mn
Sep 30, 2021 14,832.00
Sep 30, 2021 14,832.00
Jun 30, 2021 1.12 Mn
Jun 30, 2021 1.12 Mn
Mar 31, 2021 -1.23 Mn
Mar 31, 2021 -1.23 Mn
Dec 31, 2020 6.52 Mn
Dec 31, 2020 6.52 Mn
Sep 30, 2020 8,515.00
Sep 30, 2020 8,515.00
Jun 30, 2020 50,145.00
Jun 30, 2020 50,145.00
Mar 31, 2020 3,843.00
Mar 31, 2020 3,843.00
Dec 31, 2019 4.80 Mn
Dec 31, 2019 4.80 Mn
Sep 30, 2019 3.73 Mn
Sep 30, 2019 3.73 Mn
Jun 30, 2019 537,345.00
Jun 30, 2019 537,345.00
Mar 31, 2019 -339,000.00
Mar 31, 2019 -339,000.00
Dec 31, 2018 -245,000.00
Dec 31, 2018 -245,000.00